Pfizer Inc - Net Worth and Insider Trading

Pfizer Inc Net Worth

The estimated net worth of Pfizer Inc is at least $326 Million dollars as of 2024-12-27. Pfizer Inc is the 10% Owner of SpringWorks Therapeutics Inc and owns about 4,593,847 shares of SpringWorks Therapeutics Inc (SWTX) stock worth over $171 Million. Pfizer Inc is the 10% Owner of Rhythm Pharmaceuticals Inc and owns about 1,427,639 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $81 Million. Pfizer Inc is also the 10% Owner of Allogene Therapeutics Inc and owns about 22,032,040 shares of Allogene Therapeutics Inc (ALLO) stock worth over $48 Million. Besides these, Pfizer Inc also holds Pyxis Oncology Inc (PYXS) , Imara Inc (IMRA) , Quince Therapeutics Inc (QNCX) , Neoleukin Therapeutics Inc (NLTX) , ICU Medical Inc (ICUI) . Details can be seen in Pfizer Inc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pfizer Inc has not made any transactions after 2023-03-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Pfizer Inc

Pfizer Inc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Pfizer Inc owns 22 companies in total, including Quince Therapeutics Inc (QNCX) , Imara Inc (IMRA) , and SpringWorks Therapeutics Inc (SWTX) among others .

Click here to see the complete history of Pfizer Inc’s form 4 insider trades.

Insider Ownership Summary of Pfizer Inc

Ticker	Comapny	Transaction Date	Type of Owner
QNCX	Quince Therapeutics Inc	2020-06-03	10 percent owner
IMRA	Imara Inc	2020-03-16	10 percent owner
SWTX	SpringWorks Therapeutics Inc	2019-09-17	10 percent owner
		2018-11-15	director & 10 percent owner
		2018-10-15	10 percent owner
		2017-10-10	10 percent owner
		2015-09-30	10 percent owner
		2015-08-10	10 percent owner
		2014-02-18	10 percent owner
		2014-01-29	10 percent owner
		2013-09-17	10 percent owner
		2013-06-24	10 percent owner
		2007-08-27	10 percent owner
		2003-12-17	10 percent owner
		2003-04-16	10 percent owner
		2020-08-06	10 percent owner
		2020-10-27	10 percent owner
		2020-12-15	10 percent owner
		2023-03-17	10 percent owner
		2022-12-23	10 percent owner
		2020-03-11	10 percent owner
		2023-03-20	10 percent owner

Pfizer Inc Latest Holdings Summary

Pfizer Inc currently owns a total of 8 stocks. Among these stocks, Pfizer Inc owns 4,593,847 shares of SpringWorks Therapeutics Inc (SWTX) as of September 17, 2019, with a value of $171 Million and a weighting of 52.4%. Pfizer Inc owns 1,427,639 shares of Rhythm Pharmaceuticals Inc (RYTM) as of October 10, 2017, with a value of $81 Million and a weighting of 24.79%. Pfizer Inc also owns 22,032,040 shares of Allogene Therapeutics Inc (ALLO) as of October 15, 2018, with a value of $48 Million and a weighting of 14.68%. The other 5 stocks Pyxis Oncology Inc (PYXS) , Imara Inc (IMRA) , Quince Therapeutics Inc (QNCX) , Neoleukin Therapeutics Inc (NLTX) , ICU Medical Inc (ICUI) have a combined weighting of 8.12% among all his current holdings.

Latest Holdings of Pfizer Inc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SWTX	SpringWorks Therapeutics Inc	2019-09-17	4,593,847	37.14	170,615,478
RYTM	Rhythm Pharmaceuticals Inc	2017-10-10	1,427,639	56.54	80,718,709
ALLO	Allogene Therapeutics Inc	2018-10-15	22,032,040	2.17	47,809,527
PYXS	Pyxis Oncology Inc	2023-03-17	7,032,770	1.62	11,393,087
IMRA	Imara Inc	2020-03-16	1,557,722	6.32	9,844,803
QNCX	Quince Therapeutics Inc	2020-06-03	2,879,973	1.75	5,039,953
NLTX	Neoleukin Therapeutics Inc	2015-08-10	48,770	3.49	170,207
ICUI	ICU Medical Inc	2018-11-15	0	156.46	0

Holding Weightings of Pfizer Inc

Pfizer Inc Form 4 Trading Tracker

According to the SEC Form 4 filings, Pfizer Inc has made a total of 0 transactions in SpringWorks Therapeutics Inc (SWTX) over the past 5 years. The most-recent trade in SpringWorks Therapeutics Inc is the acquisition of 50,000 shares on September 17, 2019, which cost Pfizer Inc around $900,000.

According to the SEC Form 4 filings, Pfizer Inc has made a total of 0 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years. The most-recent trade in Rhythm Pharmaceuticals Inc is the acquisition of 40,000 shares on October 10, 2017, which cost Pfizer Inc around $680,000.

According to the SEC Form 4 filings, Pfizer Inc has made a total of 0 transactions in Allogene Therapeutics Inc (ALLO) over the past 5 years. The most-recent trade in Allogene Therapeutics Inc is the acquisition of 55,556 shares on October 15, 2018, which cost Pfizer Inc around $1 Million.

More details on Pfizer Inc's insider transactions can be found in the Insider Trading History of Pfizer Inc table.

Insider Trading History of Pfizer Inc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Pfizer Inc Trading Performance

GuruFocus tracks the stock performance after each of Pfizer Inc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pfizer Inc is 30.77%. GuruFocus also compares Pfizer Inc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Pfizer Inc within 3 months outperforms 4 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Pfizer Inc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Pfizer Inc

Average Return

Average return per transaction

Outperforming Transactions

4 out of 7 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	6.17
Relative Return to S&P 500(%)	1.54

Pfizer Inc Ownership Network

Ownership Network List of Pfizer Inc

No Data

Ownership Network Relation of Pfizer Inc

Pfizer Inc Owned Company Details

What does Quince Therapeutics Inc do?

Who are the key executives at Quince Therapeutics Inc?

Pfizer Inc is the 10 percent owner of Quince Therapeutics Inc. Other key executives at Quince Therapeutics Inc include director & Chief Executive Officer Dirk Thye , Chief Business Officer Brendan Hannah , and President Charles S. Ryan .

Quince Therapeutics Inc (QNCX) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Quince Therapeutics Inc (QNCX). Other recent insider transactions involving Quince Therapeutics Inc (QNCX) include a net purchase of 500,436 shares made by David Lamond , a net purchase of 322,500 shares made by Dirk Thye , and a net purchase of 110,686 shares made by Brendan Hannah .

In summary, during the past 3 months, insiders sold 0 shares of Quince Therapeutics Inc (QNCX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Quince Therapeutics Inc (QNCX) were sold and 990,009 shares were bought by its insiders, resulting in a net purchase of 990,009 shares.

Quince Therapeutics Inc (QNCX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Quince Therapeutics Inc Insider Transactions

No Available Data

What does Imara Inc do?

Who are the key executives at Imara Inc?

Pfizer Inc is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imara Inc (IMRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does SpringWorks Therapeutics Inc do?

Who are the key executives at SpringWorks Therapeutics Inc?

Pfizer Inc is the 10 percent owner of SpringWorks Therapeutics Inc. Other key executives at SpringWorks Therapeutics Inc include Chief Business Officer Badreddin Edris , director & Chief Executive Officer Saqib Islam , and Chief People Officer Daniel Pichl .

SpringWorks Therapeutics Inc (SWTX) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in SpringWorks Therapeutics Inc (SWTX). Other recent insider transactions involving SpringWorks Therapeutics Inc (SWTX) include a net sale of 147,000 shares made by Saqib Islam , a net sale of 60,000 shares made by Badreddin Edris , and a net sale of 41,181 shares made by Daniel Pichl .

In summary, during the past 3 months, insiders sold 69,000 shares of SpringWorks Therapeutics Inc (SWTX) in total and bought 0 shares, with a net sale of 69,000 shares. During the past 18 months, 263,303 shares of SpringWorks Therapeutics Inc (SWTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 263,303 shares.

SpringWorks Therapeutics Inc (SWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

SpringWorks Therapeutics Inc Insider Transactions

No Available Data

What does ICU Medical Inc do?

Who are the key executives at ICU Medical Inc?

Pfizer Inc is the director & 10 percent owner of ICU Medical Inc. Other key executives at ICU Medical Inc include VP & GM-Infusion Capital Daniel Woolson , director & Chairman and CEO Vivek Jain , and Chief Operating Officer Christian B. Voigtlander .

ICU Medical Inc (ICUI) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in ICU Medical Inc (ICUI). Other recent insider transactions involving ICU Medical Inc (ICUI) include a net sale of 90,000 shares made by Vivek Jain , a net sale of 44,103 shares made by Christian B. Voigtlander , and a net sale of 54,289 shares made by George A Lopez .

In summary, during the past 3 months, insiders sold 50,324 shares of ICU Medical Inc (ICUI) in total and bought 0 shares, with a net sale of 50,324 shares. During the past 18 months, 1,864,277 shares of ICU Medical Inc (ICUI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,864,277 shares.

ICU Medical Inc (ICUI)'s detailed insider trading history can be found in Insider Trading Tracker table.

ICU Medical Inc Insider Transactions

No Available Data

What does Allogene Therapeutics Inc do?

Who are the key executives at Allogene Therapeutics Inc?

Pfizer Inc is the 10 percent owner of Allogene Therapeutics Inc. Other key executives at Allogene Therapeutics Inc include director & 10 percent owner Arie Belldegrun , CHIEF FINANCIAL OFFICER Geoffrey M. Parker , and GENERAL COUNSEL Earl Martin Douglas .

Allogene Therapeutics Inc (ALLO) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Allogene Therapeutics Inc (ALLO). Other recent insider transactions involving Allogene Therapeutics Inc (ALLO) include a net sale of 46,417 shares made by Deborah M. Messemer , a net sale of 20,421 shares made by Franz B Humer , and a net purchase of 1,724,137 shares made by Arie Belldegrun .

In summary, during the past 3 months, insiders sold 18,357 shares of Allogene Therapeutics Inc (ALLO) in total and bought 0 shares, with a net sale of 18,357 shares. During the past 18 months, 76,838 shares of Allogene Therapeutics Inc (ALLO) were sold and 1,724,327 shares were bought by its insiders, resulting in a net purchase of 1,647,489 shares.

Allogene Therapeutics Inc (ALLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Allogene Therapeutics Inc Insider Transactions

No Available Data

What does Rhythm Pharmaceuticals Inc do?

Who are the key executives at Rhythm Pharmaceuticals Inc?

Pfizer Inc is the 10 percent owner of Rhythm Pharmaceuticals Inc. Other key executives at Rhythm Pharmaceuticals Inc include EVP & Head of North America Jennifer Chien , Chief Technical Officer Joseph Shulman , and Chief Human Resources Officer Pamela J. Cramer .

Rhythm Pharmaceuticals Inc (RYTM) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Rhythm Pharmaceuticals Inc (RYTM). Other recent insider transactions involving Rhythm Pharmaceuticals Inc (RYTM) include a net sale of 184,943 shares made by Joseph Shulman , a net sale of 145,755 shares made by Jennifer Chien , and a net sale of 85,162 shares made by Pamela J. Cramer .

In summary, during the past 3 months, insiders sold 89,517 shares of Rhythm Pharmaceuticals Inc (RYTM) in total and bought 0 shares, with a net sale of 89,517 shares. During the past 18 months, 672,183 shares of Rhythm Pharmaceuticals Inc (RYTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 672,183 shares.

Rhythm Pharmaceuticals Inc (RYTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rhythm Pharmaceuticals Inc Insider Transactions

No Available Data

What does Synlogic Inc do?

Who are the key executives at Synlogic Inc?

Pfizer Inc is the 10 percent owner of Synlogic Inc. Other key executives at Synlogic Inc include Chief Operating Officer Antoine Awad , Chief Financial Officer Michael Vangsted Jensen , and Chief Medical Officer Aoife Brennan .

Synlogic Inc (SYBX) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Synlogic Inc (SYBX). Other recent insider transactions involving Synlogic Inc (SYBX) include a net sale of 267 shares made by , and a net sale of 372 shares made by Antoine Awad .

In summary, during the past 3 months, insiders sold 79 shares of Synlogic Inc (SYBX) in total and bought 0 shares, with a net sale of 79 shares. During the past 18 months, 639 shares of Synlogic Inc (SYBX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 639 shares.

Synlogic Inc (SYBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synlogic Inc Insider Transactions

No Available Data

What does Neoleukin Therapeutics Inc do?

Who are the key executives at Neoleukin Therapeutics Inc?

Pfizer Inc is the 10 percent owner of Neoleukin Therapeutics Inc. Other key executives at Neoleukin Therapeutics Inc include 10 percent owner Baker Bros. Advisors Lp , Principal Accounting Officer Sean Michael Smith , and Chief Medical Officer Priti Patel .

Neoleukin Therapeutics Inc (NLTX) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Neoleukin Therapeutics Inc (NLTX). Other recent insider transactions involving Neoleukin Therapeutics Inc (NLTX) include a net purchase of 2,285,342 shares made by Baker Bros. Advisors Lp , and a net sale of 1,323 shares made by Sean Michael Smith .

In summary, during the past 3 months, insiders sold 0 shares of Neoleukin Therapeutics Inc (NLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 66 shares of Neoleukin Therapeutics Inc (NLTX) were sold and 114,267 shares were bought by its insiders, resulting in a net purchase of 114,201 shares.

Neoleukin Therapeutics Inc (NLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neoleukin Therapeutics Inc Insider Transactions

No Available Data

What does Flexion Therapeutics Inc do?

Who are the key executives at Flexion Therapeutics Inc?

Pfizer Inc is the 10 percent owner of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include Chief Regulatory Officer Kerry Wentworth , Chief Strategy Officer Christina Willwerth , and General Counsel Mark S. Levine .

Flexion Therapeutics Inc (FLXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Flexion Therapeutics Inc Insider Transactions

No Available Data

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Pfizer Inc is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Five Prime Therapeutics Inc do?

Who are the key executives at Five Prime Therapeutics Inc?

Pfizer Inc is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Biotechnology Value Fund L P , 10 percent owner Bvf Gp Holdings Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .

Five Prime Therapeutics Inc (FPRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Five Prime Therapeutics Inc Insider Transactions

No Available Data

What does Zoetis Inc do?

Who are the key executives at Zoetis Inc?

Pfizer Inc is the 10 percent owner of Zoetis Inc. Other key executives at Zoetis Inc include Executive Vice President Robert J Polzer , Executive Vice President Roxanne Lagano , and Executive Vice President Kristin C Peck .

Zoetis Inc (ZTS) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Zoetis Inc (ZTS). Other recent insider transactions involving Zoetis Inc (ZTS) include a net sale of 14,018 shares made by Roxanne Lagano , a net sale of 39,000 shares made by Kristin C Peck , and a net sale of 4,656 shares made by Robert J Polzer .

In summary, during the past 3 months, insiders sold 3,477 shares of Zoetis Inc (ZTS) in total and bought 0 shares, with a net sale of 3,477 shares. During the past 18 months, 68,949 shares of Zoetis Inc (ZTS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 68,949 shares.

Zoetis Inc (ZTS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zoetis Inc Insider Transactions

No Available Data

What does EyePoint Pharmaceuticals Inc do?

Who are the key executives at EyePoint Pharmaceuticals Inc?

Pfizer Inc is the 10 percent owner of EyePoint Pharmaceuticals Inc. Other key executives at EyePoint Pharmaceuticals Inc include director & President and CEO Nancy Lurker , SVP & Chief Commercial Officer David Scott Jones , and Chief Medical Officer Dario A. Paggiarino .

EyePoint Pharmaceuticals Inc (EYPT) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in EyePoint Pharmaceuticals Inc (EYPT). Other recent insider transactions involving EyePoint Pharmaceuticals Inc (EYPT) include a net sale of 943,936 shares made by Ew Healthcare Partners, L.p. , a net sale of 121,307 shares made by Dario A. Paggiarino , and a net purchase of 4,794,057 shares made by Cormorant Asset Management, Lp .

In summary, during the past 3 months, insiders sold 0 shares of EyePoint Pharmaceuticals Inc (EYPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,229,810 shares of EyePoint Pharmaceuticals Inc (EYPT) were sold and 4,817,297 shares were bought by its insiders, resulting in a net purchase of 587,487 shares.

EyePoint Pharmaceuticals Inc (EYPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

EyePoint Pharmaceuticals Inc Insider Transactions

No Available Data

What does Arqule Inc do?

Who are the key executives at Arqule Inc?

Pfizer Inc is the 10 percent owner of Arqule Inc. Other key executives at Arqule Inc include CFO and Treasurer Marc Schegerin , See Remarks Brian Schwartz , and director & Chief Executive Officer Paolo Pucci .

Arqule Inc (ARQL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Arqule Inc (ARQL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arqule Inc (ARQL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Arqule Inc (ARQL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arqule Inc Insider Transactions

No Available Data

What does InSite Vision Inc do?

Who are the key executives at InSite Vision Inc?

Pfizer Inc is the 10 percent owner of InSite Vision Inc. Other key executives at InSite Vision Inc include Vice President and CFO Louis Drapeau , 10 percent owner Coliseum Capital Management, Llc , and 10 percent owner Pinto Tv Gp Co Llc .

InSite Vision Inc (INSV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of InSite Vision Inc (INSV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of InSite Vision Inc (INSV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

InSite Vision Inc (INSV)'s detailed insider trading history can be found in Insider Trading Tracker table.

InSite Vision Inc Insider Transactions

No Available Data

What does Viatris Inc do?

Who are the key executives at Viatris Inc?

Pfizer Inc is the 10 percent owner of Viatris Inc. Other key executives at Viatris Inc include See Remarks Paul Campbell , director & President Rajiv Malik , and Global General Counsel Brian Roman .

Viatris Inc (VTRS) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Viatris Inc (VTRS). Other recent insider transactions involving Viatris Inc (VTRS) include a net sale of 949,960 shares made by Rajiv Malik , a net sale of 16,000 shares made by Andrew Cuneo , and a net sale of 51,278 shares made by Paul Campbell .

In summary, during the past 3 months, insiders sold 26,925 shares of Viatris Inc (VTRS) in total and bought 0 shares, with a net sale of 26,925 shares. During the past 18 months, 1,413,126 shares of Viatris Inc (VTRS) were sold and 4,403 shares were bought by its insiders, resulting in a net sale of 1,408,723 shares.

Viatris Inc (VTRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viatris Inc Insider Transactions

No Available Data

What does Cerevel Therapeutics Holdings Inc do?

Who are the key executives at Cerevel Therapeutics Holdings Inc?

Pfizer Inc is the 10 percent owner of Cerevel Therapeutics Holdings Inc. Other key executives at Cerevel Therapeutics Holdings Inc include director & See Remarks N Anthony Coles , Chief Scientific Officer John Renger , and Chief Medical Officer Ramiro Sanchez .

Cerevel Therapeutics Holdings Inc (CERE) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Cerevel Therapeutics Holdings Inc (CERE). Other recent insider transactions involving Cerevel Therapeutics Holdings Inc (CERE) include a net sale of 577,506 shares made by N Anthony Coles , a net sale of 37,652 shares made by Ramiro Sanchez , and a net sale of 24,572 shares made by Scott Akamine .

In summary, during the past 3 months, insiders sold 0 shares of Cerevel Therapeutics Holdings Inc (CERE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 714,262 shares of Cerevel Therapeutics Holdings Inc (CERE) were sold and 17,422,701 shares were bought by its insiders, resulting in a net purchase of 16,708,439 shares.

Cerevel Therapeutics Holdings Inc (CERE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cerevel Therapeutics Holdings Inc Insider Transactions

No Available Data

What does BioAtla Inc do?

Who are the key executives at BioAtla Inc?

Pfizer Inc is the 10 percent owner of BioAtla Inc. Other key executives at BioAtla Inc include director & 10 percent owner & Chief Executive Officer Short Jay M Phd , See Remarks Christian Vasquez , and director & President Scott Andrew Smith .

BioAtla Inc (BCAB) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in BioAtla Inc (BCAB). Other recent insider transactions involving BioAtla Inc (BCAB) include a net purchase of 6,000 shares made by Sylvia Mcbrinn , a net purchase of 50,000 shares made by Short Jay M Phd , and a net purchase of 20,000 shares made by Lawrence Steinman .

In summary, during the past 3 months, insiders sold 0 shares of BioAtla Inc (BCAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioAtla Inc (BCAB) were sold and 83,495 shares were bought by its insiders, resulting in a net purchase of 83,495 shares.

BioAtla Inc (BCAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioAtla Inc Insider Transactions

No Available Data

What does Pyxis Oncology Inc do?

Who are the key executives at Pyxis Oncology Inc?

Pfizer Inc is the 10 percent owner of Pyxis Oncology Inc. Other key executives at Pyxis Oncology Inc include Chief Financial Officer Pamela Ann Connealy , Chief Accounting Officer Jitendra Wadhane , and director & Chief Executive Officer Lara Sullivan .

Pyxis Oncology Inc (PYXS) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Pyxis Oncology Inc (PYXS). Other recent insider transactions involving Pyxis Oncology Inc (PYXS) include a net purchase of 120,276 shares made by Pamela Ann Connealy , a net purchase of 10,000 shares made by Jitendra Wadhane , and a net sale of 36,558 shares made by Lara Sullivan .

In summary, during the past 3 months, insiders sold 0 shares of Pyxis Oncology Inc (PYXS) in total and bought 88,850 shares, with a net purchase of 88,850 shares. During the past 18 months, 36,558 shares of Pyxis Oncology Inc (PYXS) were sold and 130,276 shares were bought by its insiders, resulting in a net purchase of 93,718 shares.

Pyxis Oncology Inc (PYXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pyxis Oncology Inc Insider Transactions

No Available Data

What does ORIC Pharmaceuticals Inc do?

Who are the key executives at ORIC Pharmaceuticals Inc?

Pfizer Inc is the 10 percent owner of ORIC Pharmaceuticals Inc. Other key executives at ORIC Pharmaceuticals Inc include Chief Business Officer Pratik S Multani , Chief Financial Officer Dominic Piscitelli , and director & President and CEO Jacob Chacko .

ORIC Pharmaceuticals Inc (ORIC) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in ORIC Pharmaceuticals Inc (ORIC). Other recent insider transactions involving ORIC Pharmaceuticals Inc (ORIC) include a net sale of 139,199 shares made by Jacob Chacko , a net sale of 14,133 shares made by Dominic Piscitelli , and a net sale of 14,132 shares made by Pratik S Multani .

In summary, during the past 3 months, insiders sold 42,361 shares of ORIC Pharmaceuticals Inc (ORIC) in total and bought 0 shares, with a net sale of 42,361 shares. During the past 18 months, 167,464 shares of ORIC Pharmaceuticals Inc (ORIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 167,464 shares.

ORIC Pharmaceuticals Inc (ORIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

ORIC Pharmaceuticals Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Pfizer Inc is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include Chief Financial Officer Benjamin Hohl , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 93,564 shares made by Benjamin Hohl , a net sale of 240,342 shares made by Samuel Kintz , and a net sale of 239,847 shares made by Joseph P Lyssikatos .

In summary, during the past 3 months, insiders sold 157,819 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 157,819 shares. During the past 18 months, 4,860,959 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,860,959 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

What does Zura Bio Ltd do?

Who are the key executives at Zura Bio Ltd?

Pfizer Inc is the 10 percent owner of Zura Bio Ltd. Other key executives at Zura Bio Ltd include director & 10 percent owner Parvinder Thiara , SVP & Translational Medicine Michael Howell , and EVP and CMO Christopher Cabell .

Zura Bio Ltd (ZURA) Insider Trades Summary

Over the past 18 months, Pfizer Inc made no insider transaction in Zura Bio Ltd (ZURA). Other recent insider transactions involving Zura Bio Ltd (ZURA) include a net sale of 6,801,633 shares made by Parvinder Thiara , a net purchase of 1,135,173 shares made by Someit Sidhu , and a net purchase of 159,744 shares made by Amit Munshi .

In summary, during the past 3 months, insiders sold 1,001,633 shares of Zura Bio Ltd (ZURA) in total and bought 0 shares, with a net sale of 1,001,633 shares. During the past 18 months, 6,853,361 shares of Zura Bio Ltd (ZURA) were sold and 1,437,827 shares were bought by its insiders, resulting in a net sale of 5,415,534 shares.

Zura Bio Ltd (ZURA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zura Bio Ltd Insider Transactions

No Available Data

Pfizer Inc Mailing Address

Above is the net worth, insider trading, and ownership report for Pfizer Inc. You might contact Pfizer Inc via mailing address: 66 Hudson Boulevard East, New York Ny 10001-2192.

Discussions on Pfizer Inc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.